TOP TIERMARKET NEWSWIRE

News & sentiment

IDEAYA BIOSCIENCES I (IDYA) — News & AI sentiment

IDEAYA BIOSCIENCES I (IDYA) news roundup. 2 stories in the past week, 11 over 30 days. Average 30-day sentiment is 58.6/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 1 sales totalling $985K — net selling of $985K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

2

avg sentiment 54/100

30d stories

11

avg sentiment 58.6/100

Insider net (90d)

$985K

0 buys · 1 sells

Congress (90d)

0

0 buys · 0 sells

IDYA news in the last 24 hours, 7 days, 30 days and 90 days

How much IDYA coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	IDYA stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	2	54/100	IDYA headlines →
Last 30 days	11	58.6/100	IDYA headlines →
Last 90 days	34	58/100	IDYA headlines →

Latest stories on IDYA

Citizens reiterates Ideaya Biosciences stock rating on darovasertib data

Investing.com Analyst Ratings50 · neutralanalyst

1d ago

Ideaya Biosciences announces updated clinical results from IDE849 trial

The Fly58 · neutralproduct/pr

5d ago

Ideaya Biosciences presents updated data from three darovasertib studies

The Fly58 · neutralproduct/pr

Oct 19

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

StockTitan64 · neutralproduct/pr

Oct 19

Citizens reiterates Ideaya Biosciences stock rating ahead of ESMO

Investing.com Analyst Ratings50 · neutralanalyst

Oct 19

William Blair initiates Ideaya Biosciences stock with outperform rating

Investing.com Analyst Ratings63 · neutralanalyst

Oct 16

Ideaya Biosciences initiated with an Outperform at William Blair

The Fly63 · neutralanalyst

Oct 16

IDEAYA resumed at Buy at Stifel on combo treatment for uveal melanoma

Seeking Alpha63 · neutralanalyst

Oct 14

Stifel initiates Ideaya Biosciences stock with buy rating

Investing.com Analyst Ratings63 · neutralanalyst

Oct 13

Ideaya Biosciences resumed with a Buy at Stifel

The Fly63 · neutralanalyst

Oct 13

Cantor Fitzgerald reiterates Ideaya Biosciences stock rating

Investing.com Analyst Ratings50 · neutralanalyst

Oct 6

Ideaya Biosciences appoints Michael White as president, R&D

The Fly55 · neutralgeneral

Sep 28

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

PR Newswire55 · neutralgeneral

Sep 28

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire50 · neutralgeneral

Sep 25

Cantor Fitzgerald reiterates Ideaya Biosciences stock rating

Investing.com Analyst Ratings50 · neutralanalyst

Sep 22

IDEAYA Biosciences, Inc. (IDYA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha56 · neutralproduct/pr

Sep 14

IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha56 · neutralgeneral

Sep 10

Guggenheim raises Ideaya Biosciences stock price target on DLL3 data

Investing.com Analyst Ratings63 · neutralanalyst

Sep 9

Ideaya Biosciences price target raised to $57 from $54 at Guggenheim

The Fly61 · neutralanalyst

Sep 9

Ideaya Biosciences doses first patient in OptimUM-11 trial

The Fly56 · neutralproduct/pr

Sep 9

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

StockTitan63 · neutralproduct/pr

Sep 9

IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences

PR Newswire56 · neutralgeneral

Sep 1

Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress

Investing.com Analyst Ratings61 · neutralanalyst

Sep 1

Ideaya Biosciences announces Type C meeting with FDA for IDE849 trial design

The Fly63 · neutralgeneral

Aug 31

IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

StockTitan73 · bullishproduct/pr

Aug 31

Open IDYA in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →